Abstract

To assess the level of expression of the apoptotic markers survivin, p53, Bcl-2 and proliferation marker MIB-1 in acute leukaemia’s by IHC in bone marrow biopsies. Methodology: It was a Descriptive cross-sectional study. The study was carried out over a one year period from 01 Jan 2022 to 01 Jan 2023. The study covered all acute leukaemia cases encountered over a 1 years period retrospectively and prospectively from 01 Jan 2022 to 01 Jan 2023. All cases of acute leukaemia who underwent bone marrow biopsy as a part of clinical evaluation. Results: In our study of 40 consecutive cases of AL, most of our cases were AML type (75%). We found statistically significant relation between apoptosis markers like p53 and Bcl-2; p53, Bcl-2 & survivin in AL cases. Acute Leukaemia’s are highly aggressive hematologic malignancies. The genesis and progression of the leukemic disease invariably involve deregulation in the apoptotic response pathway. Targeted therapies that are designed to induce apoptosis in leukemic cells are currently the most promising antileukemia strategies. We evaluated the relation between survivin expression (IHCn) and p53 mutation (both with anti-apoptotic functions) in AL cases along with the correlation of nuclear staining with other measured parameters. Conclusion: The understanding of the molecular apoptotic machinery and of its defects in AL lays the basis for developing new treatment strategies like drugs able to induce apoptosis of leukaemia cells

Description